Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

1.1.1.188: prostaglandin-F synthase

This is an abbreviated version!
For detailed information about prostaglandin-F synthase, go to the full flat file.

Word Map on EC 1.1.1.188

Reaction

(5Z,13E)-(15S)-9alpha,11alpha,15-trihydroxyprosta-5,13-dienoate
+
NADP+
=
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
 +
NADPH
 +
H+

Synonyms

17beta-hydroxysteroid dehydrogenase type 5, 17betaHSD5, 20alpha-HSD/PGFS, 20alpha-hydroxysteroid dehydrogenase/prostaglandin F-synthase, 9,11-endoperoxidase reductase, AKR1B1, AKR1B3, AKR1B7, AKR1C3, Akr1cl, aldo-keto reductase, aldo-keto reductase 1C3, aldo-ketoreductase 1B1, ALDR1, ALR2, DD1, dihydrodiol dehydrogenase 1, LBRM2904_31.2170, LemaA.00019.a.B1, m-PGFS, More, NADPH-dependent prostaglandin D2 11-keto reductase, P100/11E, PG endoperoxide reductase, PGD 11-ketoreductase, PGD2 11-ketoreductase, PGF, PGF synthase, PGF synthase I, PGF synthase II, PGF2alpha synthase, PGF2alpha-synthase, PGF2alpha-synthetic activity, PGF2S, PGFS, PGFS I, PGFS-I, PGFS-II, PGFSI, PGFSII, PGH 9-,11-endoperoxide reductase, PGH2 9,11-endoperoxidase, PGH2 9,11-endoperoxide reductase, PGH2 9-,11-endoperoxide reductase, prostaglandin 11-keto reductase, prostaglandin 11-ketoreductase, prostaglandin D2 11-ketoreductase, prostaglandin D2-ketoreductase, prostaglandin F synthase, prostaglandin F synthase I, prostaglandin F synthase II, prostaglandin F synthetase, prostaglandin F2alpha synthase, prostaglandin F2alpha-synthase, prostaglandin-D2 11-reductase, prostaglandin-F2alpha synthase, prostamide/PGF synthase, prostamide/prostaglandin F synthase, reductase, 15-hydroxy-11-oxoprostaglandin, synthetase, prostaglandin F2alpha, Tc00.1047053508461.80, Tc00.1047053511287.49, TCDM_00059, TrcrA.00019.a.B1, type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase, vas deferens protein

ECTree

     1 Oxidoreductases
         1.1 Acting on the CH-OH group of donors
             1.1.1 With NAD+ or NADP+ as acceptor
                1.1.1.188 prostaglandin-F synthase

Expression

Expression on EC 1.1.1.188 - prostaglandin-F synthase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
after treatment with estradiol, PGFS mRNA expression increases 2.9fold after 4 h and reaches a maximum level of 3.8-4.4fold after 8 to 24 h
-
AKR1B1 expression is induced by interleukin-1beta leading to a higher production of prostaglandin F2alpha
AKR1B1 shows decreased expression in neoplastic disease, AKR1B1 activity might be suppressed in tumor cells in breast cancer tissues
AKR1B3 mRNA is expressed in preadipocytes, and its level increases about 4fold at day 1 after initiation of adipocyte differentiation, and then quickly decreases the following day to a level lower than that in the preadipocytes
-
AKR1C3 expression is induced by interleukin-1beta leading to a higher production of prostaglandin F2alpha
AKR1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism. It is upregulated by its substrate, prostaglandin D2
expression is significantly up-regulated by oestradiol plus progesterone at oestrus and the mid phase of pseudopregnancy and is also up-regulated by a single treatment with progesterone at late pseudopregnancy. Simultaneous incubation with oestradiol and progesterone up-regulates prostaglandin-endoperoxide synthase PTGS2 gene expression at oestrus and mid-luteal phase. Treatment with oestradiol and /or progesterone affects neither prostaglandin F2alpha secretion nor prostaglandin F2alpha synthase expression at any phase after 12 h of culture
expression of AKR1B1 is upregulated in the fetal membranes in association with term labor, during labor tumor necrosis factor TNF upregulates the AKR1B1 protein expression
expression of the enzyme increases between P9 and P14 during the postnatal development, presumably in accordance with myelinogenesis
-
flutamide, i.e. 2-methyl-N-[4-nitro-30-(trifluoromethyl)-phenyl]propamide, causes upregulation of enzyme PGFS mRNA and protein amount in pregnant female pigs at gestation days 90 and 108, whereas PTGF receptor protein expression is greater in both gestational periods
in cultured myometrial cells there is a dose-dependent stimulatory effect of interleukin 1beta and tumor necrosis factor alpha on PTGS2, PTGES and AKR1B1, i.e.PGF synthase expression
-
interleukin IL-1beta is able to upregulate COX-2 and AKR1B1 proteins as well as prostaglandin F2alpha production under normal glucose concentrations. The promoter activity of AKR1B1 gene is increased by IL-1beta particularly around the multiple stress response region
PGF2S is constitutively expressed throughout promastigote development
PGFS mRNA in the myometrium increases during pregnancy both in the gravid and the non-gravid uterine horns
-
treatment with estradiol and/or progesterone affects neither PGF2alpha secretion nor enzyme PGFS expression at any phase after 12 h of culture, while related enzymes PG-endoperoxide synthase (PTGS2) and PGE2 synthase (PGES) are both upregulated by estradiol and progesterone during pseudopregnancy
uterine expression of isoforms AKR1C3 is up-regulated post implantation and declines prepartum
-